NKGen Biotech (NYSE:NKGN) Shares Down 2.9%

NKGen Biotech, Inc. (NYSE:NKGN) shares were down 2.9% during mid-day trading on Wednesday . The stock traded as low as $1.15 and last traded at $1.17. Approximately 70,593 shares traded hands during trading, a decline of 97% from the average daily volume of 2,060,171 shares. The stock had previously closed at $1.20.

NKGen Biotech Trading Down 7.7 %

The firm has a 50-day moving average of $1.34 and a 200-day moving average of $1.67.

NKGen Biotech (NYSE:NKGN) last posted its quarterly earnings results on Monday, May 20th. The company reported ($0.25) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On NKGen Biotech

A hedge fund recently bought a new stake in NKGen Biotech stock. Sequoia Financial Advisors LLC acquired a new position in NKGen Biotech, Inc. (NYSE:NKGN) during the first quarter, according to its most recent filing with the SEC. The firm acquired 16,000 shares of the company’s stock, valued at approximately $30,000. Sequoia Financial Advisors LLC owned about 0.07% of NKGen Biotech as of its most recent filing with the SEC. Hedge funds and other institutional investors own 76.17% of the company’s stock.

About NKGen Biotech

NKGen Biotech, Inc operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials.